Altimmune (ALT) News Today $5.99 -0.66 (-9.92%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$6.00 +0.01 (+0.25%) As of 03/3/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period B. Riley Brokers Increase Earnings Estimates for AltimmuneAltimmune, Inc. (NASDAQ:ALT - Free Report) - Equities research analysts at B. Riley lifted their FY2025 EPS estimates for Altimmune in a report released on Friday, February 28th. B. Riley analyst M. Mamtani now anticipates that the company will earn $0.86 per share for the year, up from their priMarch 4 at 2:52 AM | marketbeat.comAltimmune (NASDAQ:ALT) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $12.00 price target on shares of Altimmune in a research report on Monday.March 3 at 1:23 PM | marketbeat.comAltimmune to Participate in the Leerink Global Healthcare ConferenceMarch 3 at 7:30 AM | globenewswire.comB. Riley Has Optimistic Outlook of Altimmune FY2025 EarningsAltimmune, Inc. (NASDAQ:ALT - Free Report) - Stock analysts at B. Riley upped their FY2025 earnings estimates for shares of Altimmune in a research report issued to clients and investors on Friday, February 28th. B. Riley analyst M. Mamtani now anticipates that the company will earn $0.86 per shaMarch 3 at 2:57 AM | marketbeat.comAltimmune (NASDAQ:ALT) Coverage Initiated by Analysts at William BlairMarch 2 at 1:53 AM | americanbankingnews.comWilliam Blair Initiates Coverage of Altimmune (ALT) with Market Perform RecommendationMarch 1 at 11:22 AM | msn.comWilliam Blair Begins Coverage on Altimmune (NASDAQ:ALT)William Blair initiated coverage on shares of Altimmune in a research note on Friday. They set a "market perform" rating for the company.March 1 at 7:24 AM | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Receives $20.83 Consensus Price Target from BrokeragesMarch 1 at 1:21 AM | americanbankingnews.comAltimmune (NASDAQ:ALT) Releases Earnings Results, Beats Estimates By $0.01 EPSAltimmune (NASDAQ:ALT - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%.February 28, 2025 | marketbeat.comAltimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2February 28, 2025 | seekingalpha.comAltimmune Full Year 2024 Earnings: Revenues Beat Expectations, EPS In LineFebruary 28, 2025 | finance.yahoo.comAltimmune, Inc. (NASDAQ:ALT) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | msn.comQ4 2024 Altimmune Inc Earnings CallFebruary 28, 2025 | finance.yahoo.comAltimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 PrintFebruary 28, 2025 | msn.comAltimmune Inc (ALT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D CostsFebruary 28, 2025 | finance.yahoo.comAltimmune initiated with a Market Perform at William BlairFebruary 27, 2025 | markets.businessinsider.comAltimmune files $400M mixed securities shelfFebruary 27, 2025 | markets.businessinsider.comAltimmune, Inc. (ALT) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | seekingalpha.comAltimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateFebruary 27, 2025 | globenewswire.comAltimmune, Inc. (NASDAQ:ALT) Receives Average Rating of "Buy" from AnalystsAltimmune, Inc. (NASDAQ:ALT - Get Free Report) has been given an average recommendation of "Buy" by the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one hasFebruary 26, 2025 | marketbeat.comAltimmune appoints Teri Lawver, Jerry Durso to boardFebruary 26, 2025 | markets.businessinsider.comAltimmune Expands Board Amid Late-Stage Drug DevelopmentFebruary 25, 2025 | tipranks.comSeasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of DirectorsFebruary 25, 2025 | globenewswire.comAltimmune (ALT) to Release Earnings on ThursdayAltimmune (NASDAQ:ALT) will be releasing earnings before the market opens on Thursday, February 27, Financial Modeling Prep reports.February 22, 2025 | marketbeat.comAltimmune (NASDAQ:ALT) Shares Up 8.7% - Time to Buy?Altimmune (NASDAQ:ALT) Trading 8.7% Higher - Here's WhyFebruary 20, 2025 | marketbeat.comAltimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025February 20, 2025 | globenewswire.comAltimmune put volume heavy and directionally bearishFebruary 20, 2025 | markets.businessinsider.comAltimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASHFebruary 18, 2025 | seekingalpha.comAltimmune, Inc. (NASDAQ:ALT) Short Interest Down 5.2% in JanuaryAltimmune, Inc. (NASDAQ:ALT - Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 23,320,000 shares, a decrease of 5.2% from the January 15th total of 24,590,000 shares. Based on an average daily trading volume, of 3,190,000 shares, the short-interest ratio is presently 7.3 days.February 18, 2025 | marketbeat.comH.C. Wainwright maintains Buy on Altimmune stock, $12 targetFebruary 6, 2025 | msn.comHC Wainwright Reiterates "Buy" Rating for Altimmune (NASDAQ:ALT)HC Wainwright reiterated a "buy" rating and set a $12.00 price target on shares of Altimmune in a research note on Wednesday.February 5, 2025 | marketbeat.comWith 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big gunsFebruary 4, 2025 | uk.finance.yahoo.comAltimmune, Inc. (NASDAQ:ALT) Receives $20.83 Average Target Price from AnalystsAltimmune, Inc. (NASDAQ:ALT - Get Free Report) has been assigned a consensus rating of "Buy" from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strFebruary 4, 2025 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Buy" by AnalystsAltimmune, Inc. (NASDAQ:ALT - Get Free Report) has earned a consensus recommendation of "Buy" from the eight research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and oneFebruary 1, 2025 | marketbeat.comAltimmune to Participate in the Guggenheim SMID Cap Biotech ConferenceJanuary 29, 2025 | globenewswire.comAltimmune, Inc. (NASDAQ:ALT) Position Trimmed by Exchange Traded Concepts LLCExchange Traded Concepts LLC lessened its stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 26.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 159,573 shares of the company's stock after selling 57,188 shares during the quarter. ExJanuary 28, 2025 | marketbeat.comJPMorgan Chase & Co. Sells 191,848 Shares of Altimmune, Inc. (NASDAQ:ALT)JPMorgan Chase & Co. lowered its stake in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 65.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,912 shares of the coJanuary 28, 2025 | marketbeat.comHC Wainwright Estimates Altimmune FY2029 EarningsAltimmune, Inc. (NASDAQ:ALT - Free Report) - Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Altimmune in a note issued to investors on Wednesday, January 22nd. HC Wainwright analyst P. Trucchio anticipates that the company will earn $1.3January 28, 2025 | marketbeat.comBrokers Issue Forecasts for Altimmune FY2029 EarningsAltimmune, Inc. (NASDAQ:ALT - Free Report) - HC Wainwright issued their FY2029 earnings per share estimates for Altimmune in a research note issued on Wednesday, January 22nd. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of $1.30 for the year. HC WainwriJanuary 27, 2025 | marketbeat.comAltimmune's SWOT analysis: pemvidutide potential drives stock outlookJanuary 24, 2025 | msn.comAltimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)January 23, 2025 | benzinga.comAltimmune’s Pemvidutide: A Promising Investment with Strong Buy Rating and Potential Revenue GrowthJanuary 23, 2025 | markets.businessinsider.comAltimmune's (ALT) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $12.00 price objective on shares of Altimmune in a research report on Wednesday.January 22, 2025 | marketbeat.comEvercore ISI Keeps Their Buy Rating on Altimmune (ALT)January 8, 2025 | markets.businessinsider.comStifel Initiates Coverage of Altimmune (ALT) with Buy RecommendationJanuary 8, 2025 | msn.comPromising Prospects for Altimmune: Buy Rating Backed by Upcoming Data Readout and Strategic ExpansionJanuary 8, 2025 | markets.businessinsider.comAltimmune (NASDAQ:ALT) Shares Gap Up - What's Next?Altimmune (NASDAQ:ALT) Shares Gap Up - Here's WhyJanuary 8, 2025 | marketbeat.comAltimmune (NASDAQ:ALT) Earns Buy Rating from Analysts at Stifel NicolausStifel Nicolaus began coverage on shares of Altimmune in a research note on Wednesday. They issued a "buy" rating and a $18.00 target price on the stock.January 8, 2025 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by BrokeragesAltimmune, Inc. (NASDAQ:ALT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight ratings firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy raJanuary 7, 2025 | marketbeat.comFrom Davids to Goliaths: the GLP-1R gold rushJanuary 3, 2025 | finance.yahoo.com Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address ALT Media Mentions By Week ALT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALT News Sentiment▼0.540.70▲Average Medical News Sentiment ALT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALT Articles This Week▼278▲ALT Articles Average Week Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Galapagos News IDEAYA Biosciences News Janux Therapeutics News Tarsus Pharmaceuticals News Disc Medicine News Kiniksa Pharmaceuticals News Schrödinger News Wave Life Sciences News Arcutis Biotherapeutics News Evotec News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALT) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
